Edition:
United States

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

11.55USD
4:00pm EDT
Change (% chg)

$0.20 (+1.76%)
Prev Close
$11.35
Open
$11.35
Day's High
$11.73
Day's Low
$11.20
Volume
261,939
Avg. Vol
224,454
52-wk High
$17.30
52-wk Low
$7.25

Chart for

About

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $897.12
Shares Outstanding(Mil.): 78.01
Dividend: --
Yield (%): --

Financials

  TGTX.OQ Industry Sector
P/E (TTM): -- 95.67 30.17
EPS (TTM): -2.13 -- --
ROI: -160.75 3.33 12.67
ROE: -165.11 2.31 14.86

BRIEF-TG Therapeutics, Novimmune Announce Global Agreement For Development And Commercialization Of Anti-CD47/ Anti-CD19 bispecific antibody

* TG THERAPEUTICS AND NOVIMMUNE SA ANNOUNCE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF A NOVEL ANTI-CD47/ ANTI-CD19 BISPECIFIC ANTIBODY

Jun 20 2018

BRIEF-TG Therapeutics Reports Qtrly Loss Per Share Of $0.59

* TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

Competitors

Earnings vs. Estimates